5 (1 votes)
Healthcare Prof:
Measuring levels with the active form of the protein EGFR within the tumor and its vicinity can give a much more trustworthy prognosis for people with prostate cancer. This is what Ume? University researcher Peter Hammarsten and his associates write in a study in the leading scientific journal Clinical Cancer Study.
One of the main problems with prostate cancer is the fact that, with today’s prognosis markers, some 70-80 percent of patients wind up in a group where quite small may be mentioned about their prognosis. However, nowadays no techniques to are great enough establish which patients truly need to have therapy and which ones can get along fine without the hard remedy. This in turn implies that certain patients are over-treated with therapies that may result in serious side effects and that other patients who actually require intensive remedy don’t get it or get it too late.
In a study lately published inside the scientific journal Clinical Cancer Research, Hammarsten studied tissue biopsies from prostate tumors in 259 patients and located a new prognosis marker for prostate cancer. It’s the active type of the protein EFGR (Epidermal Growth Factor Receptor) that was shown to give data regarding the aggressiveness of the tumor, each when it’s measured within the tumor or within the healthy tissue surrounding the tumor.
EGFR belongs to the same household as the prognosis marker HER2, that is utilized right now for breast cancer to decide the aggressiveness of a tumor which is to be treated with inhibitors of HER2, that’s, the drug Herceptin. In a comparable way, it might be feasible in the future to use the active type of EGFR to choose patients having a poor prognosis and are appropriate for remedy with inhibitors of EGFR. As a way to use EGFR as a prognosis marker clinically within the future, further studies will have to target its expressions in other and bigger material in prostate tumors.
Prostate cancer may be the most frequent cancer form among guys in Sweden. Each year some 10,000 men are diagnosed with prostate cancer. Some two,500 of them will die of their disease. In other words, some patients have an aggressive fatal illness, whereas others have a slowly growing tumor that can not trigger any key troubles.
Source: Expertanswer
View drug info on Herceptin.